VIDEO: Check out the #NIAID blog for the latest updates from #AIDS2024 covering long-acting injectables, bi-directional learning, PACHA & more. Learn more: go.nih.gov/NrYJatM #PrEP 📷 credit: HIVgov

📢 Calling all researchers! ORWH, NIH OAR, & NIH partners are highlighting the urgent need for intersectional HIV research focused on women, girls, & gender-diverse populations. Read more about this NOSI here: bit.ly/3x63sCG #HIVresearch #WomensHealth

📣Deadline Approaching! NIH is investing in groundbreaking research to enhance the provision of #HIV services through pharmacies & pharmacists. Apply for research funding by August 14:  go.nih.gov/OARHIVpharm #PharmacyResearch #FundingOpportunity

🔬 Attention researchers: Health Disparities, NIH NHLBI & NIDDK have an open request for applications for research into the mechanisms that contribute to health disparities in #HIV and aging and the influence of multiple comorbidities. Learn more: bit.ly/4bM8cMk

#NIAID-supported clinical studies are assessing broadly neutralizing antibodies (#bNAbs) for clearance of #HIV from the viral reservoir. bNAbs can neutralize a wide range of HIV variants and may provide a promising path to an #HIVCure. Learn more: go.nih.gov/viKorN8

📢 Attention: People with HIV 📢 New federal guidelines suggest a screening program that uses high resolution anoscopy (HRA) to help detect and treat precancer and prevent anal cancer for people with HIV. Learn more about the benefits of screening. go.nih.gov/zD1Rnms

🔔ICYMI: The FY26 NIH #HIV/AIDS Professional Judgment Budget highlights research that could be supported with additional funding: go.nih.gov/fy25pjb

📣Deadline Today!📣 NIH is investing in groundbreaking research to enhance the provision of #HIV services through pharmacies & pharmacists. Apply for research funding by August 13: go.nih.gov/OARHIVpharm #PharmacyResearch #FundingOpportunity

Learn more about federally approved guidelines on #Breastfeeding / #Chestfeeding for people with #HIV on #ART with sustained undetectable viral load: go.nih.gov/kcxcrX4

The antiviral drug #tecovirimat did not reduce the duration of #mpox lesions among children & adults with clade I mpox in the Democratic Republic of the Congo, based on an initial analysis from the PALM007 trial. Learn more: go.nih.gov/q9OyB6v #NIAID Institut National de Recherche Biomédicale (INRB) Siga Technologies

🚨 The Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with #HIV have been updated. Send any feedback to [email protected]. Read the full guideline: bit.ly/3AnSgTf

During #AIDS2024, representatives from NIAID News and OAR held an informal “Ask the Experts” session to answer attendee questions about the NIH #HIVresearch program. Learn about this and other NIH activities: go.nih.gov/MUTLtqA

Attention researchers: Health Disparities, NIH NHLBI, & NIDDK have an open request for applications for research into the mechanisms that contribute to health disparities in #HIV and aging and the influence of multiple comorbidities. Learn more: bit.ly/4bM8cMk

OAR is pleased to support the #DEBUTchallenge with VentureWell, NIBIB, Health Disparities, National Cancer Institute, and NICHD News to nurture the spirit of inquiry and innovation that fueled this year’s submissions. Read the announcement of this year’s winners: go.nih.gov/PhdnMgG

🔎 Seeking funding for research aimed at improving quality of life and promoting successful aging in people with HIV and comorbidities who are racial and ethnic minorities and from low socioeconomic backgrounds? Apply now: bit.ly/4cIK26p

To help prevent anal cancer, experts now recommend regular assessments and a specialized screening tool for certain populations with HIV. Learn more about how these guidelines could impact your health in this summary from OAR: go.nih.gov/zD1Rnms

The #HIV/AIDS Prevention and Care #DEBUTchallenge prize is awarded to Loyola University Chicago for an IV Infusion Pump Mobile Application. This innovation could improve IV infusions used for HIV treatment. Read the announcement of this year’s winners: go.nih.gov/PhdnMgG

#DYK Health information specialists from NIH OAR provide customized, confidential answers to your questions about #HIV and #AIDS clinical trials and treatment. Call 1-800-448-0440 from 1-4 pm ET, Monday to Friday, or send an email [email protected].

OAR was pleased to join NIH colleagues at #AIDS2024 to share highlights of the NIH #HIVresearch program. Representatives from NIH participated in sessions related to #HIVAging, stigma, global health reciprocal innovation, and more: go.nih.gov/MUTLtqA

OAR is pleased to support the #DEBUTchallenge with VentureWell, NIBIB, Health Disparities, National Cancer Institute, and NICHD News to nurture the spirit of inquiry and innovation that fueled this year’s submissions. Read the announcement of this year’s winners: go.nih.gov/PhdnMgG